Tempus AI (NASDAQ:TEM) Given New $92.00 Price Target at Cantor Fitzgerald

Tempus AI (NASDAQ:TEM) had its target price increased by Cantor Fitzgerald from $80.00 to $92.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective suggests a potential upside of 17.23% from the stock’s current price.

A number of other research analysts also recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $100.00 price objective (up from $80.00) on shares of Tempus AI in a research report on Tuesday. UBS Group began coverage on Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. HC Wainwright lifted their price target on Tempus AI from $68.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Raymond James Financial set a $80.00 price target on Tempus AI in a report on Wednesday, September 2nd. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus target price of $79.37.

Tempus AI Stock Up 8.7%

NASDAQ:TEM opened at $78.48 on Tuesday. The company’s 50-day simple moving average is $70.80 and its 200-day simple moving average is $57.12. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $90.53. The stock has a market capitalization of $14.16 billion, a P/E ratio of -54.50 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter last year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was up 23.1% on a year-over-year basis. On average, equities analysts anticipate that Tempus AI will post -1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, EVP Andrew Polovin sold 22,148 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This represents a 13.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the sale, the chief executive officer owned 100,000 shares of the company’s stock, valued at $7,747,000. This represents a 71.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,256,777 shares of company stock valued at $86,356,352. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently made changes to their positions in the stock. Eagle Health Investments LP purchased a new position in shares of Tempus AI during the first quarter worth $11,588,000. Aristotle Atlantic Partners LLC acquired a new stake in shares of Tempus AI in the first quarter valued at $6,179,000. Headlands Technologies LLC acquired a new stake in shares of Tempus AI in the second quarter valued at $2,689,000. Odyssean LLC purchased a new stake in shares of Tempus AI in the 2nd quarter valued at $897,000. Finally, Canal Insurance CO raised its holdings in shares of Tempus AI by 100.0% in the 1st quarter. Canal Insurance CO now owns 40,000 shares of the company’s stock valued at $1,809,000 after buying an additional 20,000 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.